Timothy Rolph - Oct 6, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Oct 6, 2022
Transactions value $
-$673,125
Form type
4
Date filed
10/7/2022, 06:00 PM
Previous filing
Oct 4, 2022
Next filing
Oct 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $211K +10K +5.03% $21.09 209K Oct 6, 2022 Direct F1
transaction AKRO Common Stock Sale -$884K -22.5K -10.77% $39.29 186K Oct 6, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -10K -14.02% $0.00 61.3K Oct 6, 2022 Common Stock 10K $21.09 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
F3 This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 13, 2019.